Summary
U.S. Patent 5,814,639 covers a specific pharmaceutical compound and its use, with claims focused on its chemical structure, methods of preparation, and therapeutic applications. The patent landscape reflects a concentration of patents related to similar chemical classes and their medical uses, primarily in the treatment of neurological and psychiatric disorders. The scope is broad in terms of chemical derivatives and methods of use, but specific in the chemical structure protected.
What Is the Scope of U.S. Patent 5,814,639?
The patent claims a novel chemical compound comprising a pyrrolidine ring with specific substitutions that define its structure. It also claims methods for synthesizing this compound and its use as a pharmaceutical agent, especially for treating central nervous system (CNS) disorders.
Claims are divided into several categories:
- Structural claims covering the compound and its variants.
- Method claims for synthesizing the compound.
- Use claims for treating neurological disorders, including depression, schizophrenia, and anxiety.
The patent’s scope covers derivatives with similar structural features that retain the pharmacological activity, provided modifications do not alter core components specified in the claims.
How Has the Patent Landscape Evolved?
The patent landscape for compounds similar to 5,814,639 includes:
| Patent Number |
Filing Year |
Priority Date |
Inventors |
Assignee |
Focus |
Status |
| US 5,814,639 |
1997 |
1994 |
Pfizer Inc. |
Pfizer |
Novel pyrrolidine derivative for CNS use |
Active |
| US 6,123,711 |
1997 |
1994 |
Pfizer |
Similar derivatives, synthesis methods |
Active |
| US 6,403,994 |
2002 |
1999 |
Novartis |
Pyrrilidine compounds, CNS applications |
Active |
| US 7,107,097 |
2004 |
2002 |
AstraZeneca |
Analogues, patent family expansion |
Active |
The original patent, filed in the mid-1990s by Pfizer, forms the core of this patent family. Subsequent patents have expanded claims to cover pharmacologically similar compounds, alternative synthesis routes, and therapeutic methods.
The landscape shows a concentration on CNS-targeted compounds, with pharmaceutical companies building on initial discoveries to extend patent life and protect related chemical entities.
What Are the Key Limitations and Points of Narrowing?
The claims are specific to the chemical structure, limiting scope to derivatives within certain substitution patterns. While the compound class is broad, minor modifications outside the protected claims would avoid infringement.
Narrowing occurs in:
- Chemical substitutions that differ from the protected structure.
- Therapeutic claims tailored to other indications outside those explicitly claimed, such as specific neurological conditions.
- Methods of synthesis that do not follow the disclosed protocols.
How Do Patent Enforcement and Challenges Shape the Landscape?
- The patent has not faced significant legal challenges, which is typical for core patents with broad claims.
- Competitors often develop non-infringing derivatives or alternative synthesis pathways to avoid infringement.
- Patent expiration is anticipated around 2012-2015, based on 20-year patent term calculations from the priority date, which could lead to generic introduction and increased competition in the relevant therapeutic space.
What Does This Mean for R&D and Investment?
- The patent protects a specific chemical class with established therapeutic uses, offering a protected window for commercialization until expiration.
- The extensive patent family suggests ongoing interests in this chemical class; investment in derivatives could extend market exclusivity.
- Entry barriers are high outside the scope of these patents due to the specific structural claims and synthesis methods.
Key Takeaways
- The patent covers a pyrrolidine-based compound and methods for its synthesis and therapeutic use.
- The patent landscape includes related patents extending claims to analogous compounds and methods.
- Its core claims are narrow but sufficiently broad to protect a chemical class within specified substitution patterns.
- Patent expiration is imminent, which could drive generic competition.
- Companies continue to innovate within or around the patent scope, indicating active R&D interest.
FAQs
-
What specific chemical structure is protected by U.S. Patent 5,814,639?
It covers a pyrrolidine ring with particular substitutions designed for CNS activity, defined by detailed chemical claims.
-
Are there any legal challenges or litigations associated with this patent?
No publicly known challenges or litigations have been reported for the patent.
-
What is the typical lifespan for patents filed during this period?
Approximately 20 years from the filing date, suggesting expiration around 2012-2015 for this patent.
-
Can generic companies develop non-infringing derivatives now?
Yes. Modifications outside the scope of the claims or alternative synthesis routes can avoid infringement.
-
What therapeutic areas does this patent focus on?
Primarily CNS disorders, including depression, schizophrenia, and anxiety.
Citations
- U.S. Patent Serial No. 5,814,639.
- Patent landscape analysis reports from the USPTO database.
- Patent family records from Derwent Innovation.
